CLOV vs WKHS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

CLOV

38.9
AI Score
VS
CLOV Wins

WKHS

30.7
AI Score

Investment Advisor Scores

CLOV

39score
Recommendation
AVOID NEW MONEY

WKHS

31score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric CLOV WKHS Winner
Forward P/E 37.7358 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 53.1% 374.9% WKHS
Earnings Growth 0.0% 19043.5% WKHS
Tradestie Score 38.9/100 30.7/100 CLOV
Profit Margin 0.4% -289.0% CLOV
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.3% · 3M: +10.7% WKHS 1M: +13.2% · 3M: +13.2%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 60

RSI (14): 59.7 · Price: $4.97

WKHS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 67

RSI (14): 67.4 · Price: $3.44

Fundamentals Snapshot

Metric CLOV WKHS
Market Cap — —
Forward P/E 27.6 -1.8
Trailing P/E 493.0 —
Revenue (TTM) — —
Revenue Growth 0.5% 3.7%
Gross Margin 0.2% -0.8%
Operating Margin 0.0% -5.5%
EPS 0.01 -6.61
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLOV is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.